Vectura was established in 1997 to identify and develop opportunities in drug formulation and delivery.  Vectura has evolved into a product development company that focuses on the development of pharmaceutical therapies for airways diseases.



In April, Bayer launched first product incorporating Vectura's FOX® smart nebuliser technology (Breelib™)

In April, Sunovion launched UtibronTM Neohaler® in the US

VR647, in January, FDA approves IND to support Vectura's wholly-owned programme in paediatric asthma



In December, global development programme with Mundipharma signed for pMDI inhaled triple therapy (VR2076) for asthma and COPD

VR876, in December, confirmation of alternative nebulised delivery device for Bayer's Ventavis (iloprost) using adapted Vectura FOX® device

In December, Novartis signed licensing agreement for the launch of Utibron/Seebri in the US with Sunovion

In December, Novartis' CRYSTAL study confirms Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment (long-acting bronchodilators or steroid-containing combination therapies)

VR730, in November, announced a further collaboration with Hikma for the development of generic salmeterol for the US

In September, new analysis from Novartis FLAME study confirmed Ultibro® Breezhaler® consistently more effective than Seretide® in reducing COPD flare-ups across different patient groups

In July, Lyon manufacturing facility returns to the Vectura Group

In June, Ablynx exercised option to license Vectura's FOX® device for use in its Phase IIb efficacy study of its inhaled anti-RSV Nanobody®  (ALX-0171)

Announced recommended All Share Merger with Skyepharma PLC in March, the deal completed on 10 June.

In May, Vectura announced collaboration with Propeller Health for the development of connect LOMI DPI device.

VR465, in May, Ablynx reported positive top line Phase I/IIa study results.

VR475 recruitment in Phase III Clinical Study underway.

VR942 enrolment into Phase I Clinical Study commenced and completion of this was announced in June.

VR315, completed Clinical Study in January and confirmed partner on this programme and VR506 as Hikma Pharmaceuticals PLC. In April the ANDA was accepted for filing by the US FDA and provided Hikma with a GDUFA goal date of 10 May 2017.


Global development and licence agreement with Janssen Biotech, VR096, announced. 

VR942 Phase I Clinical study commenced.  Ongoing EU/RoW launches of AirFluSal® Forspiro® by Sandoz continue.  Vectura announces successful pre-IND meeting with the US FDA regarding VR647.  Further development milestones received on generics pipeline programmes, VR315 and VR632 and further progress on pipeline programmes with milestones paid on VR876, VR632 and completion of target enrolment of the first-in-infant Phase I/IIa safety study by Ablynx on the VR465 programme.  Novartis confirmed commencement of first Phase III trial of inhaled triple therapy QVM149 for asthma triggering a milestone payment to Vectura and the US FDA approved Utibron™ Neohaler® (QVA149) and Seebri™ Neohaler® (NVA237).


AirFluSal® Forspiro® launched in the EU by Sandoz. Vectura acquired Activaero GmbH and raised £52m. Vectura signs a further US collaboration agreement with a leading international pharmaceutical company (existing undisclosed partner for VR315 US) for the VR506 asthma therapy. Novartis submit regulatory applications to US FDA for QVA149 and NVA237


Ultibro® Breezhaler® (QVA149) and Seebri® Breezhaler® (NVA237) launched by Novartis in EU and Japan. Establishment of Kinnovata joint venture in China. Initiated co-development deal with UCB for a novel molecule, VR942. Our partner Sandoz granted first marketing authorisation for AirFluSal® Forspiro® (VR315 EU & ROW) in Denmark


Seebri® Breezhaler® (NVA237) approved in EU and Japan. Novartis announces positive Phase III data for QVA149


Novartis announces positive NVA237 Phase III data and files in Europe and Japan. In August, Vectura licenses VR315 ROW rights to Sandoz and VR315 US rights to an undisclosed partner


Vectura regains US rights to VR315 from Sandoz.  GSK licenses some of Vectura’s dry powder drug formulation patents. Vectura closes laboratory facilities in Nottingham and consolidates formulation activities on the Chippenham site


Vectura's partner Novartis commenced Phase III studies with NVA237


Vectura and its partners announce positive Phase II data for NVA237. Sandoz was confirmed as partner for the generic asthma/COPD product VR315


Vectura acquired Innovata plc. In July, Vectura moves from AIM to the Official List on the London Stock Exchange


Institutional placing raising £45m.  Vectura signed partner agreement with Sandoz for VR315 - EU and US


Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237


Vectura is listed on the London Stock Exchange on AIM


Vectura acquired the Aspirair® inhaler technology and associated device engineering team from Cambridge Consultants Ltd.  Vectura moved to its current head office in Chippenham, Wiltshire, UK


Vectura signed a collaboration with Arakis Ltd (later acquired by Sosei) in the development of AD237 (later NVA237) for the treatment of COPD


Founded by Merlin and then acquired operations from Bath University through issues of shares. Vectura also acquired Co-ordinated Drug Development Limited and the Centre for Drug Formulation Studies. These acquisitions provided formulation expertise, an intellectual property estate, a development services business, and a team of research scientists

back to top